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0929-6441/ª 2014, Elsevier Taiwan LLBackground: The main outcome of virus-related hepatitis is progression to liver fibrosis. There-
fore, early diagnosis is very important in the treatment and management of patients. Although
liver biopsy is the gold standard test for assessment of liver fibrosis, it is expensive and has
some disadvantages such as sampling errors, interobserver variability, and a significant mortal-
ity and morbidity rate. Moreover, this method is invasive and has side effects, especially if it
needs repeated sampling. In order to come up with a reliable noninvasive modality in place of
biopsy, we studied the value of grayscale ultrasonography (US) and Doppler ultrasonography
(DS) for the diagnosis of liver fibrosis in patients with chronic viral hepatitis.
Patients and methods: Sixty patients, 43 with chronic hepatitis B and 17 with chronic hepatitis
C, were enrolled in this study. Grayscale US and DS were performed for all patients in the week
prior to liver biopsy. Ultrasonographic findings were recorded according to a US scoring system,
and they were compared with histological findings after liver biopsy.
Results: A total of 35 male (mean age: 36.1  10.1 years) and 25 female (mean age:
36.1  10.4 years) patients were studied. Forty-three patients had chronic hepatitis B and
the others had chronic hepatitis C. The overall grayscale US score was abnormal (ranged from
1 to 7) in 63.3% of patients and normal (0) in the other patients. The mean portal vein velocity
ranged from 8.1 cm/s to 31.7 cm/s (mean: 17.1  5.1 cm/s). The right hepatic vein diameter
ranged from 2.8 mm to 8 mm (mean: 5.1  1.2 mm). The total DS score was abnormal (1 or 2) in
66.7% of patients. Quantitative US parameters that were related more significantly to the his-
topathological staging scores of liver fibrosis were mean portal vein velocity, right hepatic vein
diameter, and gallbladder wall thickness. The total grayscale US score, DS score, andeclare that there are no conflicts of interest.
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124 Y. Davoudi et al.accumulation of US and DS scores (USeDS score) were significantly different between patients
with liver fibrosis and those without fibrosis (pZ 0.03, pZ 0.03, and p < 0.001, respectively).
We found that the total grayscale US score, DS score, and USeDS score are significantly corre-
lated with liver fibrosis stages.
Conclusion: Based on these findings, one can conclude that US may be an accurate, noninva-
sive alternative modality for the diagnosis of liver fibrosis, with fewer side effects than biopsy.
It may be especially useful for repetitive follow-up of patients.
ª 2014, Elsevier Taiwan LLC and the Chinese Taipei Society of Ultrasound in Medicine.
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Chronic viral hepatitis is a common cause of hepatic fibrosis
and cirrhosis [1e3]. Accurate determination of the amount
of fibrosis has significant therapeutic and prognostic roles in
the management of patients with chronic viral hepatitis [4].
Although liver biopsy is the gold standard test for the
assessment of liver fibrosis [5], it is invasive and has a sig-
nificant mortality and morbidity rate. The complication
rate of hepatic biopsy ranges from 1% to 5%, and its mor-
tality ranges from 1 in 1000 to 1 in 10,000 [6e8]. In addi-
tion, liver biopsy is associated with significant sampling
error and interobserver variability [9,10]. It is estimated
that liver biopsy leads to false-negative results in 20e30% of
patients [11e13]. Therefore, finding a reliable, noninvasive
procedure that can be used repeatedly in follow-up for
differentiation between liver fibrosis and cirrhosis seems to
be important. Ultrasonography (US) is considered a nonin-
vasive and inexpensive method for the diagnosis of focal
and diffuse parenchymal diseases of the liver. Although US
can detect liver cirrhosis in patients with decompensated
liver function, it is not a suitable method for detecting
acute changes [14e16]. These findings led to the study of
several noninvasive laboratory and imaging methods for
accurate determination of the amount of liver fibrosis in
recent years. However, the diagnostic value of US and
grayscale findings has not been fully investigated in a large
series of patients. In this study, we assessed the value of
the combination of grayscale and Doppler ultrasonographic
findings in the diagnosis of liver fibrosis in patients with
chronic viral hepatitis.
Materials and methods
Patients
In this cross-sectional study, conducted from June 2011 to
February 2013, 60 patients with chronic viral hepatitis who
were candidate for liver biopsy in the Gastroenterology
Department of Imam Reza Hospital, hospital were enrolled
according to the purposive sampling technique. Based on
Hung et al’s [14] study, using the formula:
NZzð1a=2Þ2  Pð1 pÞ

d2;
we chose a sample size of 30 patients. Inclusion criteria
were positive serum hepatitis B virus surface antigen(HBsAg) or antihepatitis C virus antibody along with
abnormal serum alanine transaminase level in the past 6
months. Patients were excluded if they had any clinical
and/or biochemical evidence of decompensated hepatic
function or portal hypertension, known hepatic diseases of
other etiology, and a history of oral contraceptive pills or
other drugs known to be hepatotoxic, or any drugs with
hemodynamic changes that may affect Doppler results.
This study was approved by the Ethical Committee of
Mashhad University of Medical Sciences, Mashhad, Iran (no.:
87543). All patients had a signed informed consent form.
US examination
Grayscale and Doppler ultrasonography (DS) were per-
formed by a Hitachi EUB 525 for all patients during the
week prior to liver biopsy, with a 7.5 MHz linear and
3.5 MHz curved probes for grayscale US and a 3.5 MHz
curved probe for DS.
The patients fasted for 6 hours prior to examination, and
then were studied in supine and left posterior oblique po-
sitions. The radiologist who was blinded about the patho-
logical results of the patients performed the examination.
Spleen and liver sizes; diameters of portal vein, intra-
hepatic veins, and splenic vein; and gallbladder wall
thickness were measured in millimeters. Liver surface and
hepatic parenchyma echogenicity were also recorded dur-
ing grayscale US. Doppler parameters such as portal and
hepatic vein blood velocities and directions, and wave
patterns of blood flow were studied.
These variables were scored according to the ultraso-
nographic scoring system that has been summarized in
Table 1 [14,17e19]. The total grayscale US score and DS
score were calculated by the summation of individual
scores for different variables that had been measured.
Similarly, the total USeDS score was calculated from the
sum of grayscale US and DS scores.
Percutaneous liver biopsy
Liver biopsy of the anterior segment of right lobe was
performed by a hepatologist using a 16-gauge Tru-cut bi-
opsy needle. Specimens were processed, and serial
paraffin-embedded sections were prepared.
After staining with hematoxylin and eosin, an experi-
enced hepatopathologist who was blinded to the ultraso-
nographic findings of the patients reviewed the specimens.
Table 1 Grayscale scoring system.
Score Liver
length
Echo pattern Echogenicity Liver
surface
Spleen
length
(mm)
GB wall
thickness
(mm)
Main portal
vein
diameter (mm)
Hepatic vein
diameter (mm)
Splenic vein
diameter (mm)
0 150 mm Homogeneous Normal Smooth 130 3 13 4e10 10
1 <150 mm Heterogeneous Mildly
increased
Irregular >130 >3 >13 <4 or >10 or
nonvisible
>10
2 Moderately
increased
3 Severely
increased
GB Z gallbladder.
Table 2 Baseline characteristics of patients.
Fibrosis
stage
Parameters
Number of
patients (male)
Age (y) Hepatitis
B, n (%)
Hepatitis
C, n (%)
0 15 (11) 31.7  8.2 13 (86.7) 2 (13.3)
1 15 (9) 39.6  8.2 12 (80.0) 3 (20.0)
2 10 (5) 34.1  10.0 8 (80.0) 2 (20.0)
3 12 (7) 31.5  7.4 7 (58.3) 5 (41.7)
4 3 (2) 43.6  18.6 1 (33.3) 2 (66.7)
5 3 (2) 37.0  12.0 1 (33.3) 2 (66.7)
6 2 (1) 53.5  9.19 1 (50.0) 1 (50.5)
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Histological stage of the fibrosis and grade of the necroin-
flammation were scored according to the Ishak’s Modified
Histologic Activity Index on a scale of 0e6 for fibrosis and
0e18 for necroinflammation [20]. Necroinflammatory
scores consist of periportal or periseptal interface hepatitis
(piecemeal necrosis) scores (0e4); confluent necrosis
scores (0e6); focal (spotty) lytic necrosis, apoptosis, and
focal inflammation scores (0e4); and finally portal inflam-
mation scores (0e4).
Statistical analysis
The results were analyzed by the SPSS version11.5 software
(SPSS Inc., Chicago, IL, USA). Numerical variables were
described as mean  standard deviation. For the compari-
son of means in different groups, univariate analysis and
StudenteNewmaneKeuls test were used. For the categori-
cal variables, nonparameter analysis was used for the
comparison. A p value < 0.05 was considered statistically
significant. Logistic regression, Spearman’s correlation,
KruskaleWallis test, and ManneWhitney test were used for
analysis. Sensitivity, specificity, and positive predictive
values of the US scoring system were calculated and
compared with the results of the liver fibrosis stages.
Results
A total of 60 patients with a mean age of 35.6  10.1 years
were investigated. Baseline characteristics of patients are
presented in Table 2.
Forty-five patients had abnormal liver specimens (75%)
and different degrees of liver fibrosis. We found different
ultrasonographic findings in different stages of liver
fibrosis. A nonhomogeneous echo pattern in the liver was
found in 35% of patients (n Z 21). Staging of liver fibrosis
was significantly related to the liver echo pattern
(p Z 0.001). Liver parenchyma echogenicity was slightly
increased in 21.7% of patients, moderately increased in
21.7% of patients, and severely increased in 5% of patients
(Fig. 1). Echogenicity was related significantly to staging of
liver fibrosis (p Z 0.001). Liver surface appearance was
irregular in 5% of patients and was related significantly to
liver fibrosis progression (p < 0.001). Gallbladder wallthickness was abnormal in patients with liver fibrosis and
related to pathological staging (p Z 0.02).
Right hepatic vein diameters ranged from 2.8 mm to
8 mm (mean: 5.1  1.2 mm) and revealed a significant
correlation with staging and grading of liver fibrosis
(p Z 0.004 and p Z 0.019, respectively). No relation was
found between splenic vein, portal vein, left and middle
hepatic vein diameters, splenic size, and the severity of
liver fibrosis. The overall grayscale US score was normal (0)
in 36.7% of patients and abnormal (1e7) in 63.3% of pa-
tients. The total grayscale US score was significantly
different between patients with liver fibrosis and those
without fibrosis (p Z 0.03).
In Doppler study, the mean portal vein velocity ranged
from 8.1 cm/s to 31.7 cm/s (mean: 17.1  5.1 cm/s).
A mean velocity of 15e18 cm/s was considered normal,
and the cutoff value for portal vein velocity was considered
15 cm/s.
The mean portal vein velocity was abnormal in 40 pa-
tients (67.7%). The mean velocity of portal vein varied
significantly in various stages of liver fibrosis (p Z 0.01).
Wave patterns of hepatic veins and portal vein were normal
in all patients (Figs. 2 and 3). The total DS scores were
significantly different between patients with liver fibrosis
and those without fibrosis (pZ 0.03). In addition, we found
a significant correlation between the severity of liver
fibrosis and the USeDS score (p < 0.001, r Z 0.6).
An analysis of variance test showed a significant differ-
ence between grayscale US and Doppler US scores between
different fibrosis stages (p Z 0.000 and p Z 0.004,
respectively; Table 3).
Fig. 3 Normal hepatopetal flow in the main portal vein of a
patient (Doppler score Z 0).
Fig. 1 Heterogeneous echogenicity in the liver parenchyma
with a moderate increase in the overall echogenicity. Liver
surface: smooth; spleen length: 110 mm; GB wall thickness,
2 mm; MPV: 11 mm; MHV: 6 mm; SV: 8 mm (grayscale
score Z 3). GB Z gallbladder; MHV Z hepatic vein diameter;
MPV Z mean portal vein velocity; SV Z splenic vein.
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results (Fig. 4), 1.5 is an appropriate cutoff point for
grayscale US score, while it is 0.5 for Doppler US score for
the prediction of the severity of liver fibrosis (Table 4).
To investigate the effect of simultaneous presence of US
score and DS score parameters on fibrosis stages, logistic
regression was used, which showed that the liver paren-
chymal echogenicity is the only parameter that is signifi-
cantly related to fibrosis stages (95% confidence interval
0.011e0.738, p Z 0.025).
Discussion
Viral hepatitis is a common cause of liver fibrosis world-
wide. Some studies showed that 25e45% of patients with
chronic viral hepatitis may develop liver cirrhosis and he-
patocellular carcinoma [21]. Although liver biopsy is the
gold standard method for its diagnosis, it is invasive and hasFig. 2 Mean hepatic diameter (4.7 mm), which emphasizes a
criterion for grayscale scoring (grayscale score Z 0).many complications. One of the most probable limitations
of histological classification may be that liver tissue fibrotic
changes do not always occur homogeneously, so a degree of
failure can be present even at the level of the biopsy
specimen. In recent studies, many authors suggest various
noninvasive alternative methods such as serological tests or
imaging methods. We studied the role of conventional US
and DS as noninvasive methods for the diagnosis of liver
fibrosis in 60 patients.
In our study, echo patterns of liver parenchyma and liver
surface as well as liver parenchyma echogenicity were all
related significantly to staging and severity of liver fibrosis.
These results are compatible with Shen et al’s [18] and
Zheng et al’s [17] studies. Zheng et al [17] used US in
chronic hepatitis patients for the evaluation of hepatic
inflammation and fibrosis degree, and compared them with
the histopathological findings. They found that in moderate
fibrosis, the diagnostic accuracy of ultrasound was signifi-
cantly higher than that of serology. However, no significant
difference was found between mild and severe fibrosis by
the general diagnostic US. In addition, in Shen et al’s [18]
study, in patients with various stages of liver fibrosis, the
echo pattern of liver parenchyma and the distribution of
heterogeneous echogenicity was related to the severity of
fibrosis.Table 3 Mean and range of grayscale and Doppler US
scores in each fibrosis stage.
Fibrosis stage Grayscale US score Doppler US score
Mean  SD Range Mean  SD Range
0 0.73  0.79 0e2 0.60  0.82 0e2
1 1.40  1.59 0e5 0.60  0.73 0e2
2 1.70  1.76 0e5 1.30  0.82 0e2
3 1.58  1.88 0e5 1.08  0.51 0e2
4 6.00  1.00 5e7 1.33  0.57 1e2
5 4.66  1.52 3e6 2.00  0.00 2e2
6 4.00  1.41 3e5 2.00  0.00 2e2
SD Z standard deviation; US Z ultrasonography.
Fig. 4 ROC curve for grayscale ultrasonography score and
Doppler ultrasonography for predicting the severity of liver
fibrosis. ROC Z receiver-operating characteristic.
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histogenesis, anatomy, and function, which lead to
accompaniment of viral hepatitis and biliary disorders. We
also found a significant relation between gallbladder wall
thickness and liver fibrosis staging, which was in agreement
with other studies [17,22]. However, the mechanism is yet
not clear. Although some factors such as direct invasiveness
of hepatitis virus, immunity injury, secondary infections,
and edema of the gallbladder might have a role in portal
hypertension, circumfluence obstruction of the gallbladder
vein, etc..
We did not find any correlation between the length of
the spleen and fibrous staging of liver, which is contrary to
the findings of Aube et al’s [23] study. However, Shen et al
[18] did not report any correlation between the spleen
length and fibrosis staging score; however, they showed
that the length of the spleen began to increase at S3 of liver
fibrosis, but the length at S4 was not significantly different
from that at S3.
Although diameters of all hepatic veins determined by
grayscale US were correlated with liver fibrosis staging in
Zheng et al’s [17] study, in our research, this correlation was
inverse and was found only in case of the right hepatic vein.
In other words, the more the staging of liver fibrosis, the
less the diameter of the right hepatic vein in grayscale US.Table 4 Diagnostic value of grayscale ultrasonography score a
fibrosis.
Parameters and cutoff value Sensitivity Specificity Accu
Grayscale ultrasonography
score (1.5)
40.0 100 0.68
Doppler ultrasonography
score (0.5)
75.6 60 0.66Similar to Gaiani et al’s [21], Hung et al’s [14], and
Nishiura et al’s [19] study, we found a significant correlation
between total grayscale score and liver fibrosis. In Hung
et al’s [14] study, US scores correlated significantly with
hepatic fibrosis scores (p < 0.05), in which the mean fibrosis
scores were 0.95, 1.24, 2.35, 2.95, 3.8, and 3.7 in patients
with US scores of 4, 5, 6, 7, 8, and 9 or more, respectively. An
important point of Nishiura et al’s [19] study is that indi-
vidual parameters of US scores, such as liver edge, liver
surface, and liver parenchymal texture, were significantly
correlated with fibrosis stages determined based on the bi-
opsy findings, but the total US scores of these three pa-
rameters were found to be the most reliable indicators
(Spearman Rank-order Coefficient (rs): 0.9524).
The role of chronic viral involvement of liver in alterna-
tion of hemodynamic pattern of liver vascularity is a subject
of controversy. A few studies showed a consistent relation-
ship between DS findings and liver histology. Despite of
Smith and Sterling’s [24] study, Haktanir and coworkers [25]
showed that Doppler US findings are sensitive to hemody-
namic changes in liver fibrosis. These controversies may be
related to the lack of a standard evaluating protocol for
Doppler assessment along with the influence of different
factors such as patient’s age, extension of fibrosis, as well as
cause of liver disease on hemodynamic indexes of hepatic
vessels. In our study, Doppler US scoring was significantly
related to liver fibrosis staging. Similar to Aube et al’s [23]
study, our data also showed a significant reverse correla-
tion between the velocities of the main portal vein and
fibrous staging of the liver.
So far, no study has evaluated a combined application of
grayscale US and DS findings as a scoring system. The main
strength of our research is that it was a prospective study,
and our patients were uniform in a single etiology. In
addition, we studied only nonalcoholic patients with no
evidence of decompensated liver disease, in order to
exclude the effect of alcohol steatosis and sever fibrosis in
US findings. The limitation of our investigation was that the
samples size was small; a future study should be conducted
with a larger sample size.
In conclusion, in this study, we found that in the US
scoring of the liver, liver parenchyma echogenicity was the
only parameter related to fibrosis stages in logistic regres-
sion; therefore, liver parenchyma echogenicity may be
enough and simple for use in clinical practice.
More importantly, we found that a combined USeDS
scoring system could be a useful method for evaluating liver
fibrosis. Further studies should be designed to evaluate the
value of US findings in predicting liver fibrous staging innd Doppler ultrasonography base on cut-off points for liver
racy Positive
predictive
value
Negative
predictive
value
Positive
likelihood
ratio
Negative
likelihood
ratio
2 0.100 0.35 d 0.6
9 0.44 0.84 1.89 0.4
128 Y. Davoudi et al.different types of chronic liver diseases. Establishing a
standard US liver fibrosis scoring system will help clinicians
to avoid invasive liver biopsies.
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